A strategic partnership between Circular Genomics and Vitazi.ai aims to enhance early detection of Alzheimer’s disease through innovative diagnostic technologies.
The collaboration seeks to merge artificial intelligence-driven retinal imaging with blood-based RNA biomarkers to identify individuals at risk for Alzheimer’s. This partnership addresses existing gaps in early-stage patient identification and aims to create a comprehensive diagnostic framework.
The proposed workflow involves a two-step clinical approach. Initially, AI-powered retinal imaging will be employed in primary care settings to identify patients with elevated risk. Following this, blood samples will be analyzed for brain-derived circular RNA (circRNA) biomarkers to confirm early signs of the disease.
This initiative is expected to yield multimodal machine learning models that integrate retinal imaging data with biomarker profiles, providing a deeper understanding of Alzheimer’s biology. The use of circRNA is particularly promising due to its stability and ability to provide insights into disease pathways, potentially revolutionizing how neurodegenerative diseases are understood and treated.
The implications of this collaboration extend beyond Alzheimer’s, potentially paving the way for advancements in precision neurology and improving early intervention strategies across various neurodegenerative conditions.